These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16549330)

  • 1. What's new in pancreatic cancer treatment pipeline?
    Von Hoff DD
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):315-26. PubMed ID: 16549330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
    Burris H; Rocha-Lima C
    Oncologist; 2008 Mar; 13(3):289-98. PubMed ID: 18378539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
    Wang ZY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
    [No Abstract]   [Full Text] [Related]  

  • 4. Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
    Hampton T
    JAMA; 2007 Jul; 298(3):273-5. PubMed ID: 17635880
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
    Wich C; Agaimy A; Strobel D; Wissniowski TT; Hartmann A; Ocker M
    World J Gastroenterol; 2010 Jul; 16(28):3592-6. PubMed ID: 20653070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
    Yokoba M; Yanase N; Masuda N
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):783-8. PubMed ID: 15984516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
    Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
    Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
    Petrelli A; Giordano S
    Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
    Siu LL; Awada A; Takimoto CH; Piccart M; Schwartz B; Giannaris T; Lathia C; Petrenciuc O; Moore MJ
    Clin Cancer Res; 2006 Jan; 12(1):144-51. PubMed ID: 16397036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
    Lee SJ; Lee J; Park SH; Park JO; Park YS; Kang WK; Lee J; Yim DS; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1540-7. PubMed ID: 21695438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
    Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
    Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular therapy of pancreatic cancer.
    Plentz RR; Manns MP; Greten TF
    Minerva Endocrinol; 2010 Mar; 35(1):27-33. PubMed ID: 20386525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Non-surgical treatment for pancreatic cancer].
    Okusaka T; Ueno H; Ikeda M; Morizane C
    Nihon Shokakibyo Gakkai Zasshi; 2006 Apr; 103(4):391-7. PubMed ID: 16629457
    [No Abstract]   [Full Text] [Related]  

  • 15. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 16. [The progress of chemotherapy for advanced pancreatic cancer].
    Ioka T; Katayama K; Ashida R; Takahashi H; Teshima T; Sakon M
    Nihon Shokakibyo Gakkai Zasshi; 2015 Dec; 112(12):2119-26. PubMed ID: 26638783
    [No Abstract]   [Full Text] [Related]  

  • 17. Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
    Saif MW
    Nat Rev Gastroenterol Hepatol; 2014 Jan; 11(1):8-9. PubMed ID: 24322903
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting EGFR in bilio-pancreatic and liver carcinoma.
    Fratto ME; Santini D; Vincenzi B; Silvestris N; Azzariti A; Tommasi S; Zoccoli A; Galluzzo S; Maiello E; Colucci G; Tonini G
    Front Biosci (Schol Ed); 2011 Jan; 3(1):16-22. PubMed ID: 21196353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.